Description
Tafinlar (Dabrafenib) 50mg Online
Tafinlar (Dabrafenib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat melanoma, non-small cell lung cancer, and thyroid cancer. Tafinlar is used alone or in combination with trametinib to treat melanoma (skin cancer) that has spread or that cannot be removed by surgery. It is only used if the melanoma cells have the BRAF V600E or V600K mutations. Your doctor will use a special test to look for this mutation. Tafinlar belongs to the group of medicines called antineoplastics (cancer medicines).
Tafinlar may be used alone or in combination with another medication (trametinib) to treat a type of skin cancer (melanoma) that has spread or cannot be removed by surgery and has a certain type of abnormal “BRAF” gene. Tafinlar belongs to a class of drugs known as kinase inhibitors. It works by slowing the growth of skin cancer cells.
The safety of Tafinlar as a single agent was evaluated in 586 patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, previously treated or untreated, who received TAFINLAR 150 mg orally twice daily until disease progression or unacceptable toxicity, including 181 patients treated for at least 6 months and 86 additional patients treated for more than 12 months. TAFINLAR was studied in open-label, single-arm trials and in an open-label, randomized, active-controlled trial. The median daily dose of TAFINLAR was 300 mg (range: 118 to 300 mg).
